Ireland· IE-PA-EU/1/24/1826/001
Korjuny 10 micrograms concentrate for solution for infusion
A catumaxomab product containing catumaxomab, registered in Ireland by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Catumaxomab is registered in 9 of 19 countries.
Countries holding a registration under ATC L01FX03 (catumaxomab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 5 of them publish a price we can compare per daily dose
Catumaxomab · ATC L01FX03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
HPRA (Ireland)- Active substance
- Catumaxomab
- Manufacturer
- Atnahs Pharma Netherlands B.V.
- Country
- Ireland (IE)
- ATC code
- L01FX03
- ATC class
- Catumaxomab
- Defined daily dose
- 21 mcg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1826/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Catumaxomab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKorjunyAtnahs Pharma Netherlands B.V.
- NetherlandsKorjuny 10 microgram concentraat voor oplossing voor infusieAtnahs Pharma Netherlands B.V.
- SpainKORJUNY 10 MICROGRAMOS CONCENTRADO PARA SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- BelgiumKorjuny 10 µgAtnahs Pharma Netherlands
- IcelandKorjunyAtnahs Pharma Netherlands B.V.
- PolandKORJUNYLindis Biotech GmbH
- SwedenKorjuny 10 mikrogram Koncentrat till infusionsvätska, lösningAtnahs Pharma Netherlands B.V.
- CzechiaKORJUNYAtnahs Pharma Netherlands B.V., Amsterdam
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Korjuny
- Liechtenstein · Korjuny
- Norway · Korjuny
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9e60e18e-ac5b-4413-bc5a-c984a82f2353 GET /v1/drugs/9e60e18e-ac5b-4413-bc5a-c984a82f2353?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intraperitoneal use"
],
"source": "hpra",
"atc_all": [
"L01FX03"
],
"strength": null,
"pa_number": "EU/1/24/1826/001",
"substances": [
"Catumaxomab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "10/02/2025",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about catumaxomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.